Drug discovery and trial results
New targets, first-in-class candidates and the study results that change plans. Sources on every story.
Amgen's Imdelltra Combo Extends Lung Cancer Survival by 8.4 Months
In a phase 3 trial, Amgen's Imdelltra plus Imfinzi raised median survival to 21.1 months from 12.7 months in extensive-stage small cell lung cancer.
Roche's Divarasib Beats Rival KRAS Drugs, Cuts Death Risk 44%
In a phase 3 trial of 338 patients, Roche's divarasib extended survival in KRAS G12C lung cancer versus Amgen's Lumakras and BMS's Krazati.
Genmab's Rina-S Beats Chemo in Ovarian Cancer, Cuts Death Risk 57%
Genmab says its FRα-targeted drug Rina-S cut the risk of progression or death by 71% and lowered death risk versus chemotherapy in a phase 3 ovarian cancer trial.
Merck, Moderna Vaccine Combo Cuts Melanoma Relapse or Death Risk 42%
Detailed Phase 3 data show Merck and Moderna's personalized mRNA vaccine plus Keytruda lowered melanoma recurrence or death risk by 42%, below some investor hopes.
Roivant's Brepocitinib Wins Two Phase 3 Uveitis Trials
Priovant's brepocitinib cut the risk of treatment failure in two phase 3 trials in non-infectious uveitis. A US filing is planned for the first half of 2027.
Disc's Bitopertin Hits All Phase 3 Goals in Rare Light Disorder
Disc Medicine says bitopertin met every primary and secondary endpoint in its Phase 3 APOLLO trial in EPP and plans to resubmit its FDA application by year end.
Admilparant Meets Phase 3 Endpoint in IPF Trial
Admilparant 60 mg significantly improved lung function at 52 weeks in the ALOFT-IPF trial, while the higher dose missed statistical significance.
Pharmacists Take Lead Role in Lp(a) Testing, Cardiovascular Prevention
National Lipid Association emphasizes pharmacists' expanding role in prompting once-in-lifetime Lp(a) screening and optimizing statin therapy for heart disease prevention.
Polypharmacy Surge Among Older Americans Reveals Drug Interaction Risks
New research shows polypharmacy increasing among seniors while OTC use declines, raising concerns about dangerous drug-drug interactions in this vulnerable population.
Drug Repurposing Market Hits $29.4B as Industry Seeks Cost Relief
The drug repurposing market reached $29.4B in 2024, offering pharma companies a cost-effective R&D alternative amid rising development costs and tariff pressures.
OpenAI Unveils GPT-Rosalind: Frontier AI Model for Drug Discovery
OpenAI's new GPT-Rosalind model targets pharmaceutical R&D with specialized capabilities in drug discovery, genomics analysis, and protein reasoning.
GSK's $110M AI Partnership Signals New Era in Drug Discovery
GSK's collaboration with Relation Therapeutics, valued up to $110M, represents pharmaceutical industry's accelerating shift toward AI-driven research platforms.
Novo Nordisk Partners with Anthropic to Deploy AI in Drug Discovery
Pharmaceutical giant Novo Nordisk announces strategic collaboration with AI leader Anthropic, signaling industry shift toward generative AI in drug development.
Bristol Myers Squibb Achieves Positive Trial Results Amid Industry Headwinds
Bristol Myers Squibb announces successful topline results from registrational trial, marking a significant achievement as competitors face setbacks in drug development.
Pharmacists Take Lead Role in TKI Cancer Therapy Management
New clinical guidance positions pharmacists as essential partners in tyrosine kinase inhibitor therapy, marking a significant shift in oncology care delivery.
FDA Approves Daraxonrasib for Pancreatic Cancer Treatment
The FDA has granted approval to daraxonrasib (Rasonque), a once-daily oral treatment for pancreatic cancer, marking a significant therapeutic advancement for patients.
Telix Publishes Long-Term TLX400-Tx FAP Therapy Data
Telix Pharmaceuticals releases mature clinical data for TLX400-Tx FAP-targeted therapy, advancing precision oncology research with real-world evidence beyond initial trials.
Novonesis, Novo Nordisk Team Up on Microbiome Weight-Loss Research
Danish firms collaborate on groundbreaking study examining whether microbiome supplements can enhance weight-loss drug efficacy, with results expected in 2027.
Amylyx Pharmaceuticals Achieves Breakthrough in Post-Bariatric Care
Amylyx reports positive Phase 3 results for avexitide in treating post-bariatric hypoglycemia, marking the first successful trial addressing this dangerous complication.
AI-Designed Drugs Reach Phase 3 Trials in Industry Milestone
First AI-designed therapeutics enter late-stage human testing, validating artificial intelligence's role in pharmaceutical development and signaling potential transformation.